NovaBridge Biosciences: capex
| Value | {"amount": 701000, "concept": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "currency": "USD"} |
|---|---|
| Period | 2020-01-01 – 2020-09-30 |
| Status | current |
| Entity | NovaBridge Biosciences |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T18:00:43.919806+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/e4e3fdde-08b5-4cac-a17f-73859a38c8cc
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001193125-21-030570Retrieved: 2026-08-19T18:00:43.919806+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001778016/capex/2020-09-30 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/e4e3fdde-08b5-4cac-a17f-73859a38c8cc
History
- supersedes {"unit": "CNY", "value": 4761000, "concept": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment"} (evidence 0001193125-21-030570)